Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
Creciendo
La empresa se encuentra en una fase de crecimiento. Sus ingresos anuales más recientes ascienden a 1.03M USD.
Infravalorada
El PE más reciente de la empresa es -2.33, en un rango percentil bajo de 3 años.
Compra institucional
Las tenencias institucionales más recientes son 1.25M acciones, lo que supone un aumento del 13.30% con respecto al trimestre anterior.
En posesión de James Simons
El inversor estrella James Simons posee 7.96K acciones de este valor.
Menor actividad del mercado
La empresa está generando menos interés entre los inversores, con una relación de rotación de 20 días del %!.(string=-0.65)